Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Moclobemide in Continuation Treatment of Major Depressive Episodes: An Open Follow-up Study Over Six Months

GAGIANO, CARLLO ANDRIAS M Med (Psych), MD; MULLER, FRIEDEGUND GERTRUD MARGARETE MB, ChB; de KOCK, RIJK FOURIE MB, ChB; SCHALL, ROBERT PhD

Journal of Clinical Psychopharmacology: August 1995 - Volume 15 - Issue 4 - p 46S-50S
Recent Clinical Developments With Reversible And Selective Amine Oxidase Inhibitors
Buy

This was an open study of moclobemide, 300 to 450 mg daily, as continuation treatment for 18 weeks, after a 6-week randomized, double-blind acute treatment period with moclobemide administered in three different dosage regimens. The primary antidepressant efficacy criterion was the total score on the Hamilton Rating Scale for Depression. Secondary efficacy criteria were the total scores on the Hamilton Rating Scale for Anxiety and the clinical global impression of illness, severity, and efficacy. The safety of moclobemide was assessed by the type, incidence, and severity of adverse events, as well as changes from baseline in vital signs. Moclobemide as continuation treatment of patients with major depressive episodes and comorbid anxiety was efficacious over a 6-month period. There was some additional anti-depressant effect after 6 weeks of acute treatment, especially with respect to treatment response rates. Moclobemide was well tolerated, and no patient's treatment was terminated as the result of adverse events. (J Clin Psychopharmacol 1995;15[Suppl 2]:46S-50S)

Departments of (GAGIANO, MULLER) Psychiatry and (SCHALL) Pharmacology, University of the Orange Free State, Bloemfontein, and (de KOCK) Roche Products (Pty) Ltd, Johannesburg, South Africa

Address requests for reprints to: Prof. C.A. Gagiano, Department of Psychiatry, University of the Orange Free State, P.O. Box 339, Bloemfontein, 9300 South Africa.

© Williams & Wilkins 1995. All Rights Reserved.